Glympse Bio
700 Main Street
Cambridge
MA
02139
United States
Tel: 617.863.3636
Website: https://www.glympsebio.com/
Email: info@glympsebio.com
27 articles with Glympse Bio
-
Glympse to Present Data Demonstrating Sensitive Detection of Hepatocellular Carcinoma at AASLD The Liver Meeting 2022
10/25/2022
Glympse today announced that it will present a poster demonstrating that its novel protease biosensor diagnostic platform can detect hepatocellular carcinoma (HCC) at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting 2022, being held in Washington, D.C., from Nov. 4-8, 2022.
-
Glympse to Present Two Posters Demonstrating Novel Protease Biosensor Diagnostic Platform Detection of Hepatocellular Carcinoma at EASL ILC 2022
6/8/2022
Glympse to Present Two Posters Demonstrating Novel Protease Biosensor Diagnostic Platform Detection of Hepatocellular Carcinoma at EASL ILC 2022.
-
Life sciences organizations and companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Glympse Appoints Jonathan Wilde, Ph.D., as Chief Scientific Officer to Advance Biosensor Assay Platform
5/17/2022
Glympse, a biotechnology company developing revolutionary technology to diagnose and monitor disease, announced the appointment of Jonathan Wilde, Ph.D., as Chief Scientific Officer.
-
72% of employers are currently experiencing a decrease in the volume of candidates applying to their jobs.
-
This liquid biopsy uses a panel of peptide biosensors to analyze protein activity from a blood sample and provide actionable readouts of the disease state.
-
The life sciences industry might just be filling a bit richer this week as two major venture capital firms announced the closing of new funds.
-
Glympse to Present Data from First Application of New Liquid Biopsy Diagnostic Platform at AASLD's The Liver Meeting 2021
11/1/2021
Glympse, a biotechnology company developing revolutionary technology to diagnose and monitor disease, announced that it will be presenting on the new liquid biopsy approach to its biosensor platform at the American Association for the Study of Liver Disease annual The Liver Meeting, being held virtually from Nov. 12-15, 2021.
-
Glympse Appoints Tram Tran, M.D., as Chief Medical Officer
9/8/2021
Glympse, a biotechnology company developing innovative technology to improve disease diagnosis and monitoring, announced the appointment of Tram Tran, M.D., to the newly created role of Chief Medical Officer.
-
BioSpace Movers & Shakers, July 23
7/23/2021
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Glympse Bio Appoints Matthew T. Navarro, J.D., as Chief Financial Officer
7/20/2021
Glympse Bio today announced the appointment of Matthew T. Navarro , J.D., to the newly-created role of Chief Financial Officer.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Glympse Bio Names Jessica Atkinson Senior Vice President of Business Development
2/2/2021
Glympse Bio and pharmaceutical executive brings expertise leading new business initiatives and partnerships
-
Glympse Bio’s tunable biosensors are poised to be a game-changing diagnostic tool in 2021.
-
Glympse Bio Announces $46.7 Million Series B Financing
7/15/2020
Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, has closed an oversubscribed $46.7 million Series B financing. The proceeds from the financing will support continu
-
Glympse Bio secured $46.7 million in a Series B fundraising round that will be used to support continued development of the company’s novel biosensor platform in fibrotic diseases such as Non-Alcoholic Steatohepatitis (NASH), oncology, and infectious diseases.
-
Glympse Bio Presents Preclinical Data Supporting Its Technology’s Potential to Improve NASH Patient Management
11/8/2019
Data supports high diagnostic accuracy of proprietary synthetic biomarkers for early monitoring of stage of disease, disease progression and treatment response
-
BioSpace Movers & Shakers, Nov. 8
11/8/2019
Pharmaceutical, medtech and biotech companies expand their leadership teams with this week's appointments. -
Glympse Bio Names Tracey Dawson as Chief Commercial Officer and Head of Strategy
11/4/2019
Biotech and pharmaceutical executive brings expertise leading new development programs and operating models
-
Pharmaceutical Executive Francis Cuss Joins Glympse Bio Board
8/1/2019
Glympse Bio, Inc., a life science company developing in vivo activity sensors to transform disease detection, monitoring and drug response, announced today that Francis Cuss has been appointed to its Board of Directors